These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 31822778)

  • 1. Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Modvig S; Madsen HO; Siitonen SM; Rosthøj S; Tierens A; Juvonen V; Osnes LTN; Vålerhaugen H; Hultdin M; Thörn I; Matuzeviciene R; Stoskus M; Marincevic M; Fogelstrand L; Lilleorg A; Toft N; Jónsson OG; Pruunsild K; Vaitkeviciene G; Vettenranta K; Lund B; Abrahamsson J; Schmiegelow K; Marquart HV
    Leukemia; 2020 Jun; 34(6):1719-1720. PubMed ID: 31822778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; van Dongen JJM; Ottmann OG
    Leukemia; 2020 Jul; 34(7):1970. PubMed ID: 31937894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Thastrup M; Marquart HV; Levinsen M; Grell K; Abrahamsson J; Albertsen BK; Frandsen TL; Harila-Saari A; Lähteenmäki PM; Niinimäki R; Pronk CJ; Ulvmoen A; Vaitkevičienė G; Taskinen M; Schmiegelow K;
    Leukemia; 2020 Oct; 34(10):2822. PubMed ID: 32269320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Publisher Correction: Fatty acid synthase, a novel poor prognostic factor for acute lymphoblastic leukemia which can be targeted by ginger extract.
    Ghaeidamini Harouni M; Rahgozar S; Rahimi Babasheikhali S; Safavi A; Ghodousi ES
    Sci Rep; 2020 Nov; 10(1):20952. PubMed ID: 33239671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
    Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
    Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
    Shaver AC; Seegmiller AC
    Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
    Vinhas E; Lucena-Silva N; Pedrosa F
    Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction to: LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.
    Li Z; Deng M; Huang F; Jin C; Sun S; Chen H; Liu X; He L; Sadek AH; Zhang CC
    Cell Mol Immunol; 2020 Mar; 17(3):302-304. PubMed ID: 32005951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological Subtypes of Acute Lymphoblastic Leukemia- Beyond Morphology: Experience from Kidwai State Cancer Institute, Bengaluru, India.
    Rajkumar NN; Vijay RH
    J Assoc Physicians India; 2017 Jul; 65(7):14-17. PubMed ID: 28792162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.